Publications by authors named "Hessel H Van der Zee"
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.
J Eur Acad Dermatol Venereol
October 2024
Introduction: The International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool that measures inflammatory lesions, including draining tunnels, in hidradenitis suppurativa (HS).
Objective: To evaluate secukinumab efficacy using IHS4 in patients with moderate to severe HS.
Methods: Data from the SUNSHINE and SUNRISE trials, which assessed subcutaneous secukinumab 300 mg every 2 (SECQ2W) and 4 (SECQ4W) weeks in adults with moderate to severe HS, were analyzed.
Methods for describing and reporting the clinical and histologic characteristics of cutaneous tissue samples from patients with hidradenitis suppurativa (HS) are not currently standardized, limiting clinicians' and scientists' ability to uniformly record, report, and communicate about the characteristics of tissue used in translational experiments. A recently published consensus statement outlined morphological definitions of typical HS lesions, but no consensus has been reached regarding clinical characterization and examination of HS tissue samples. In this study, we aimed to establish a protocol for reporting histopathologic and clinical characteristics of HS tissue specimens.
View Article and Find Full Text PDFArticle Synopsis
- A 62-year-old male patient showed a unique spongy appearance of the perianal skin after undergoing surgery for hidradenitis suppurativa (HS), characterized by multiple orifices and cysts.
- Histopathological analysis revealed dilated hair follicles and keratin, suggesting that the spongy appearance was due to spontaneous shedding of cystic contents.
- The condition, termed "cystic sponge anus," may be linked to factors like HS, smoking, and male gender, requiring further research to understand its prevalence and related health issues.
Article Synopsis
- The global burden of hidradenitis suppurativa (HS) is poorly understood due to limited and varying prevalence data, which has been affected by different methodologies and diagnostic approaches.
- The Global Hidradenitis Suppurativa Atlas (GHiSA) aims to accurately determine HS prevalence by using a validated questionnaire for screening, followed by physician validation for positive cases, assessing about 10% of negatives for diagnostic accuracy.
- Currently, GHiSA is conducting prevalence studies in 58 countries to create a comprehensive global prevalence estimate through proportional meta-analysis, allowing for direct international comparisons that were not previously feasible.
Article Synopsis
- There are existing registries for hidradenitis suppurativa (HS) in Europe and the USA, but there is no global standard on the data collected, which complicates international collaboration.
- The goal is to create a core dataset (CDS) for global HS registries covering demographics, comorbidities, clinical findings, patient outcomes, and treatments.
- A Delphi process involving 20 experts from eight countries resulted in a consensus on 48 items to be included in all HS registries, promoting consistent data collection worldwide.
Importance: Although several clinician- and patient-reported outcome measures have been developed for trials in hidradenitis suppurativa (HS), there is currently no consensus on which measures are best suited for use in clinical practice. Identifying validated and feasible measures applicable to the practice setting has the potential to optimize treatment strategies and generate generalizable evidence that may inform treatment guidelines.
Objective: To establish consensus on a core set of clinician- and patient-reported outcome measures recommended for use in clinical practice and to establish the appropriate interval within which these measures should be applied.
Background: Hidradenitis suppurativa (HS) is a chronic, devastating, multifactorial skin disease. Patients generally develop HS after puberty and the prevalence of the disease is assumed to decrease with higher age. Data outside the usual age range are limited, especially for elderly patients.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of combining adalimumab, a biologic treatment, with surgery versus using adalimumab alone in patients with moderate to severe hidradenitis suppurativa.
- Results show that the combination treatment led to significantly better reductions in both the severity of the disease and improvements in quality of life after 12 months compared to monotherapy.
- The study has limitations, including a short follow-up period that prevents assessment of long-term surgical recurrence rates.
Background: Antibiotic resistance is a major concern, especially in hidradenitis suppurativa (HS). However, antibiotics form a cornerstone in its treatment. Topical clindamycin is known to cause bacterial resistance but is still advised as monotherapy for the treatment of mild to moderate HS.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness of guselkumab, an anti-IL-23p19 monoclonal antibody, for treating moderate-to-severe hidradenitis suppurativa (HS) over 16 weeks.
- A phase IIa trial showed that 65% of patients achieved significant clinical improvement, with decreases in Hidradenitis Suppurativa Clinical Response (HiSCR) scores and inflammatory nodules.
- Even though inflammatory markers in the skin were reduced in responders, overall patient-reported outcomes did not reflect significant improvement, and only one serious adverse event occurred, deemed likely unrelated to the treatment.
Article Synopsis
- A new parameter called IHS4-55, which indicates a 55% reduction in the severity of Hidradenitis Suppurativa (HS), was validated using data from patients treated with adalimumab and placebo.
- The research aimed to externally validate the IHS4-55 in patients treated with antibiotics, assessing its correlation with the reduction of inflammatory lesions and quality of life metrics.
- Results from a study of 283 patients showed that those achieving IHS4-55 experienced significant reductions in inflammatory nodules and had a greater likelihood of improving quality of life scores, supporting its use as a key outcome measure in clinical trials.
Background And Objective: Hidradenitis suppurativa is a chronic inflammatory skin disease that can lead to a substantial reduction in quality of life. Recent studies revealed high levels of unmet care needs of patients with hidradenitis suppurativa, but their preferences in treatment decision making have scarcely been investigated. This study aimed to reveal which treatment attributes adult patients with HS in Europe consider most important in treatment decision-making.
View Article and Find Full Text PDFArticle Synopsis
- A new dichotomous outcome measure, IHS4-55, was created and validated for assessing hidradenitis suppurativa (HS) in clinical trials and practice, focusing on a 55% reduction in the IHS4 score to indicate improvement.
- The effectiveness of the IHS4-55 was demonstrated through data from the PIONEER studies, showing that patients who met this threshold had better outcomes when treated with adalimumab compared to placebo.
- IHS4-55 shows similar performance to existing measures, providing a reliable tool for evaluating treatment responses in HS patients.
Introduction: Cohort studies on the use of retinoids for hidradenitis suppurativa (HS) have yielded contradicting results. As the clinical presentation of HS is heterogeneous, with different predilection sites and hallmark features, it can be hypothesized that HS phenotypes are associated with the effectiveness of specific retinoid treatments.
Objectives: The aim of this study was to evaluate the drug survival of oral retinoids in the treatment of HS and to establish predictors for longer treatment duration.
Background: Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored.
Objectives: To measure associations between treatment satisfaction and clinical and treatment-related characteristics among patients with HS.
Background: After excision surgery in patients with hidradenitis suppurativa (HS), wounds are usually left open for secondary intention healing. To evaluate wound healing, reliable wound measurement is important. However, digital wound measurement tools for measuring the surface area are validated for small wounds located on flat or mildly convex body surfaces in studies, often powered inadequately.
View Article and Find Full Text PDFFritsche 2022; 187:288–294.
View Article and Find Full Text PDFBackground And Objective: Hidradenitis suppurativa (HS) is an inflammatory skin disease with a profound effect on patients' quality of life. The patient's journey to manage HS is often complex and unsuccessful, which motivates the aim of this research to gain insight into unmet needs and relevant treatment considerations from the perspective of patients and healthcare professionals (HCPs).
Methods: Individual semi-structured interviews were conducted with patients and HCPs experienced in treating HS to understand the perceived unmet care needs and to identify important treatment attributes.
Article Synopsis
- Hidradenitis suppurativa (HS) is a chronic skin disease caused by inflammation in hair follicles, leading to painful nodules, abscesses, and draining tunnels filled with immune cells and inflammatory cytokines.
- Currently, adalimumab is the only approved medication for HS, despite various clinical trials exploring the effectiveness of other biologics targeting cytokines like TNF-α and IL-1.
- The review outlines evidence-based use of available biologics and small molecules in therapy, discusses integration with medical and surgical treatments, and highlights new treatment targets under investigation for managing HS.